Disclosures I have nothing to disclose Heart Failure Pearls for the - - PDF document

disclosures
SMART_READER_LITE
LIVE PREVIEW

Disclosures I have nothing to disclose Heart Failure Pearls for the - - PDF document

Disclosures I have nothing to disclose Heart Failure Pearls for the Hospitalist Ronald Witteles, M.D. Stanford University School of Medicine October 21, 2017 @Ron_Witteles Outline Patient 1 n Admission for Heart Failure


slide-1
SLIDE 1

1 “Heart Failure Pearls for the Hospitalist”

Ronald Witteles, M.D. Stanford University School of Medicine October 21, 2017

@Ron_Witteles

Disclosures

I have nothing to disclose

Outline

n Admission for “Heart Failure

Exacerbation”?

n Three different patient types, three

different problems

– How can we provide the best possible care for each patient? n Final thoughts

Patient 1

  • 68 y.o. man with dilated nonischemic cardiomyopathy
  • Baseline echo: Moderate LV dilatation, LVEF 25%
  • Comes to ER for gradually worsening SOB/edema
  • Baseline meds (stable over last 6 months):
  • Carvedilol 25 mg bid
  • Lisinopril 20 mg bid
  • Furosemide 40 mg bid
  • Spironolactone 25 mg qd
  • Digoxin 0.25 mg qd
slide-2
SLIDE 2

2 Exam & Labs

  • Physical exam:
  • Wt 90 kg (up from 85 kg one month ago)
  • BP 115/65, HR 65, SaO2 94% RA
  • Scant bibasilar crackles
  • No significant murmurs/gallops
  • 3+ LE edema
  • Labs:
  • Na 137, K 4.1, Cr 1.3 (baseline 1.4)
  • NT-Pro BNP 6100, Troponin I <0.1
  • Digoxin level (random): 0.3 (subtherapeutic)
  • CXR: Cardiomegaly, mild pulmonary edema
  • ECG: Sinus rhythm at 65 bpm, old LBBB

What Do You Do?

1) Stop digoxin 2) Continue digoxin The patient says he wants to stop any medications which aren’t clearly helping him. What do you do with the digoxin?

What Do You Do?

1) Stop digoxin 2) Continue digoxin The patient says he wants to stop any medications which aren’t clearly helping him. What do you do with the digoxin?

Digoxin – DIG Trial (1997)

  • 6800 patients with EF ≤ 45%
  • Digoxin vs. placebo
  • All patients in sinus rhythm
  • Outcomes:
  • Primary: All-cause mortality
  • Secondary: CV death, worsened HF &

hospitalizations

slide-3
SLIDE 3

3 All-Cause Mortality

Adapted from NEJM. 1997;336:525-33.

Death or HF Hospitalization

Adapted from NEJM. 1997;336:525-33.

placebo digoxin

Cochrane Review: Risk of Clinical Deterioration if Stop Dig

Adapted from Hood et al. Cochrane Library. 2004, Issue 4.

A Recent Story…

slide-4
SLIDE 4

4

  • I was nervously thinking about this talk…

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.

A Recent Story…

slide-5
SLIDE 5

5

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.
  • My headache went away. I was happy.

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.
  • My headache went away. I was happy.

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.
  • My headache went away. I was happy.
  • Note: I never thought I was going to live

longer by taking the ibuprofen.

A Recent Story…

slide-6
SLIDE 6

6

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.
  • My headache went away. I was happy.
  • Note: I never thought I was going to live

longer by taking the ibuprofen.

  • Should I have been denied the opportunity to

take the ibuprofen???

A Recent Story…

  • I was nervously thinking about this talk…
  • Will they like it?
  • Will my jokes fall flat?
  • I developed a tension headache.
  • I took 600 mg of ibuprofen.
  • My headache went away. I was happy.
  • Note: I never thought I was going to live

longer by taking the ibuprofen.

  • Should I have been denied the opportunity to

take the ibuprofen???

  • Why do we hold digoxin to such a higher

standard?

A Recent Story… What Do You Do?

What should you do with the digoxin dose?

1) Continue digoxin at 0.25 mg qd 2) Increase to 0.50 mg qd 3) Check a true digoxin trough level & increase dose to 0.50 mg qd if still subtherapeutic

What Do You Do?

What should you do with the digoxin dose?

1) Continue digoxin at 0.25 mg qd 2) Increase to 0.50 mg qd 3) Check a true digoxin trough level & increase dose to 0.50 mg qd if still subtherapeutic

slide-7
SLIDE 7

7 High Digoxin Doses: Beware Eggerthella Lenta

  • Purpose in life: To break down digoxin!
  • 1970s: 10% of individuals found to excrete inactive

dihydrodigoxin when given digoxin.

  • 1983: Manuscript in Science identifies Eubacterium

lentum as the culprit

  • “Fresh stool samples from two human volunteers

who were known to be heavy digoxin reduction product excretors were cultured anaerobically in chopped meat glucose broth containing digoxin…”

Adapted from Saha et al. Science. 1983;220:325-327.

High Digoxin Doses: Beware Eggerthella Lenta

  • Purpose in life: To break down digoxin!
  • 1970s: 10% of individuals found to excrete inactive

dihydrodigoxin when given digoxin.

  • 1983: Manuscript in Science identifies Eubacterium

lentum as the culprit

  • “Fresh stool samples from two human volunteers

who were known to be heavy digoxin reduction product excretors were cultured anaerobically in chopped meat glucose broth containing digoxin…”

  • God bless the basic scientists!!!

Adapted from Saha et al. Science. 1983;220:325-327.

An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic

An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic
slide-8
SLIDE 8

8 An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic

An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic

An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic

An Inevitable Sequence of Events...

  • Well-meaning physician targets digoxin levels

for treatment of HF or atrial fibrillation

  • A patient with eggerthella lenta ends up on an

extremely high dose of digoxin

  • Patient receives antibiotics (Z-pack, etc.)
  • Patient gets dig-toxic
  • NOTE: This is the reason for antibiotic-digoxin

medication interactions!

slide-9
SLIDE 9

9 How to Avoid This?

  • Step 1: Recognize we live in a world of antibiotics.
  • It is not realistic to think your patient will not

ultimately get an antibiotic prescription.

  • Step 2: Don’t target digoxin levels!
  • You can estimate daily dose by 2 main things:
  • GFR
  • Amiodarone use
  • Nobody should require a maintenance dose > 0.25 mg
  • Remember: For the most part, low levels are okay!
  • Particularly true if using for heart failure

indication rather than rate control

  • Reasons for checking digoxin levels:
  • You suspect toxicity
  • To check medication adherence

DIG Trial: Post-hoc Analysis of Mortality

  • vs. 1-month Digoxin Levels

Adapted from Adams et al. J Am Coll Cardiol. 2005;46:497-504.

What Do You Do?

What about the lisinopril?

1) Continue lisinopril unchanged 2) Decrease lisinopril dose to 10 mg bid 3) Change lisinopril to ARB 4) Stop lisinopril & start sacubitril/valsartan next day 5) Change lisinopril to ARB x 36 hours, then change to sacubitril/valsartan

What Do You Do?

What about the lisinopril?

1) Continue lisinopril unchanged 2) Decrease lisinopril dose to 10 mg bid 3) Change lisinopril to ARB 4) Stop lisinopril & start sacubitril/valsartan next day 5) Change lisinopril to ARB x 36 hours, then change to sacubitril/valsartan

slide-10
SLIDE 10

10 PARADIGM-HF

  • Neprilysin: Breaks down natriuretic peptides &

angiotensin II

  • Trial: Sacubitril-valsartan vs. Enalapril
  • Double-blind, randomized trial of 8442 patients
  • LVEF ≤ 40%
  • NYHA II-IV
  • Primary end-point: Time to CV death or HF

hospitalization

  • Stopped early after median follow-up of 27 months
  • ACC/AHA/HFSA Guidelines:
  • SWITCH NYHA Class 2-3 HFrEF patients

from ACEi or ARB to sacubitril-valsartan (Class 1 recommendation!)

Adapted from McMurray et al. New Engl J Med. 2014;371:993-1004.

Breakdown of Outcomes

Adapted from McMurray et al. New Engl J Med. 2014;371:993-1004.

Breakdown of Outcomes

Adapted from McMurray et al. New Engl J Med. 2014;371:993-1004.

Breakdown of Outcomes

Adapted from McMurray et al. New Engl J Med. 2014;371:993-1004.

slide-11
SLIDE 11

11

What You Should Be Asking Yourself… Which systolic HF patients should I not be putting on sacubitril/valsartan?

Practicalities of Use

  • Greater BP drop than with ACEi or ARB

alone

  • Must be off of ACEi for at least 36 hours

(angioedema risk)

  • All the more reason to get away from ACEi for

new heart failure patients

  • Make sure insurance approval in place!

Adapted from McMurray et al. New Engl J Med. 2014;371:993-1004.

Dietary Restrictions

What diet should you recommend?

1) Eat however you want! 2) Fluid restricted 3) Sodium restricted 4) Sodium & fluid restricted 5) Sodium & fluid & saturated fat restricted 6) Sodium & fluid & sugar & saturated fat restricted

Dietary Restrictions

What diet should you recommend?

1) Eat however you want! 2) Fluid restricted 3) Sodium restricted 4) Sodium & fluid restricted 5) Sodium & fluid & saturated fat restricted 6) Sodium & fluid & sugar & saturated fat restricted

slide-12
SLIDE 12

12

American Dietetic Association: HF Diet Guidelines

n “Fluid intake should be between 1.4

and 1.9 L per day.”

n “Fluid restriction will improve clinical

symptoms and quality of life.”

Adapted from http://www.guidelines.gov/content.aspx?id=12988

Google Search: “Heart Failure Diet Recommendations”

n Cleveland Clinic:

– “Limit of 2 liters per day, ‘Even if you feel thirsty.’”

n UCSF: “If you drink too much fluid, your body’s

water content may increase and make your heart work harder.”

n Emory: “You may be restricted to no more than 2

quarts of fluid per day. Fluid restrictions apply to beverages, high-moisture fruits, yogurt, pudding, ice cream, ice cubes, and any food that melts into a liquid… Even if you are thirsty, do not drink more than the recommended allowance. Instead, you should suck on frozen lemon wedges to quench your thirst.”

Other Dietary Advice

n Brigham & Women’s Hospital:

– “Limit fluid to 2 quarts” – “Your fluid restriction may at times leave you with thirst and a dry mouth. Here are a few suggestions to try:”

§ “Eat fresh juicy fruits such as watermelon, grapes, oranges, peaches, etc. However, if you consume more than 3 servings/day of these juicy fruits, count each additional serving as fluid. (1 cup fruit = ½ cup fluid)” § “Freeze or partially freeze pieces of fruit, like lemon wedges dipped in sugar, for a refreshing treat.” § “Chill mouthwash and gargle for a fresh feeling.”

Trial of Free-Fluid (FF) vs. Fluid-Restriction (FR) in Treatment of Patients Admitted with ADHF

Adapted from Travers et al. J Card Fail. 2007;13:128-132.

* Time to clinical stability = symptomatic improvement with no evidence of fluid

  • verload, stable weight x 48h, off IV therapies x 48h, no change in cardiac medications

for 48h.

slide-13
SLIDE 13

13 Outpatients & Fluid Restriction

n Randomized, cross-over study n Patients (n=65): – CHF with LVEF <45% – Stable outpatients without clinical signs of significant volume overload n Intervention (cross-over at mid-study): – Restricted fluid group: Maximum intake of 1.5 L/day x 16 weeks – Liberalized fluid group: Advised to limit intake to weight-based intake (averaged 2.4-2.8 L/day) x 16 weeks

Adapted from Holst et al. Scandinavian Cardiovascular Journal. 2008;42:316-22.

Results

n Diuretic changes: – Restricted fluid group: 13 increases, 9 decreases – Liberalized fluid group: 9 increases, 9 decreases n Hospitalizations: 5 (restricted) vs. 5 (liberalized) n No change in Na, Cr, weight, 6-minute walk

Adapted from Holst et al. Scandinavian Cardiovascular Journal. 2008;42:316-22.

10 20 30 40 50 60 Restricted fluid Liberalized fluid

% of Patients

Sense of Thirst

Adapted from Holst et al. Scandinavian Cardiovascular Journal. 2008;42:316-22.

P<0.001 5 10 15 20 25 30 Restricted fluid Liberalized fluid

% of Patients

Reported Difficulty to Adhere to Restriction

Adapted from Holst et al. Scandinavian Cardiovascular Journal. 2008;42:316-22.

P<0.001

slide-14
SLIDE 14

14 Conclusion re: Sodium/Fluid Intake

  • When there is a problem, it is too

much sodium, not too much water!

  • Do not waste time/energy on fluid

restricting unless patient is hyponatremic

  • Patient’s non-restricted water intake is

based on maintaining sodium concentration… if he/she takes in less salt, he/she will take in less water.

  • Best advice (in normonatremic patient):

Drink to quench thirst – not more, not less.

How to Institute Low Na Diet

  • Most patients think low

fat/sugar diet is most important for them.

  • Multiple techniques to do

low sodium diet.

  • My advice: Stop the milligram

counting!

  • Best diet – fresh

meat/fruits/vegetables

  • Nothing prepackaged/nothing

that anyone has had the

  • pportunity to add salt to.

Is Any Device Therapy Indicated?

1) Consult for implantable loop monitor placement 2) Consult for ICD placement 3) Consult for biventricular pacemaker/ICD placement 4) No device therapy is indicated

Is Any Device Therapy Indicated?

1) Consult for implantable loop monitor placement 2) Consult for ICD placement 3) Consult for biventricular pacemaker/ICD placement 4) No device therapy is indicated

slide-15
SLIDE 15

15 COMPANION Trial (2004)

  • 1520 patients
  • NYHA Class III-IV
  • LVEF ≤ 35%
  • QRS ≥ 120 ms, PR > 150 ms
  • Median QRS duration 160 ms
  • Randomized to medical therapy vs. biventricular

pacemaker vs. biventricular pacemaker/ICD

  • Median f/u: 29.4 months
  • Primary endpoint: Death or hospitalization

COMPANION Trial: Survival Without Hospitalization

Adapted from Bristow et al. NEJM. 2004;350:2140-50. P<0.001

COMPANION Trial: Survival

Adapted from Bristow et al. NEJM. 2004;350:2140-50. P<0.001

CARE-HF Trial

  • 813 patients
  • NYHA Class III-IV
  • LVEF ≤ 35%
  • QRS ≥ 150 ms or 120-149 ms with additional echo criteria
  • Most patients = LBBB, Median QRS = 160 ms
  • Randomized to resynchronization vs. no

resynchronization

  • No ICD therapy
  • Median f/u: 29.4 months
  • Primary endpoint: All-cause mortality or CV

hospitalization

slide-16
SLIDE 16

16

CARE-HF Trial: Survival Without CV Hospitalization

Adapted from Cleland et al. NEJM. 2005;352:1539-49. P<0.001

CARE-HF Trial: Overall Survival

Adapted from Cleland et al. NEJM. 2005;352:1539-49. P<0.002

A Concerning Lab...

You have diuresed the patient to apparent euvolemia. Repeat NT-proBNP = 4000. What should you do based on this result? 1) Discharge the patient as planned 2) Push forward with further diuresis 3) Further uptitrate neurohormonal antagonists

A Concerning Lab...

You have diuresed the patient to apparent euvolemia. Repeat NT-proBNP = 4000. What should you do based on this result? 1) Discharge the patient as planned 2) Push forward with further diuresis 3) Further uptitrate neurohormonal antagonists

slide-17
SLIDE 17

17 TIME-CHF Trial

  • 499 patients age >60 with NYHA II-IV

HF

  • All with HF hospitalizations within past

year

  • Intervention: Symptom-guided

management or NT-proBNP-guided therapy

  • Primary endpoints:
  • 18 month survival free of

hospitalization

  • Quality of life at 18 months

Adapted from Pfisterer et al. JAMA 2009;301:383-92.

No Difference in Hospital-Free Surivival

Adapted from Pfisterer et al. JAMA 2009;301:383-92.

No Difference in QOL (If Anything – Better Without NT-BNP!)

Adapted from Pfisterer et al. JAMA 2009;301:383-92.

Minnesota Living with Heart Failure Score

BOT-AcuteHF Trial

  • 271 patients hospitalized for ADHF, randomized

2006-2010

  • Patients first treated with usual care until clinical

stability, then randomized to:

  • Conventional treatment (blinded to NT-proBP

measurement), or

  • NT-proBNP-guided treatment
  • If NT-proBNP ≥ 3000 ng/L à treatment intensified

(more neurohormonal blockade, inotrope treatment, and/or more loop diuretics)

  • Primary endpoint:
  • CV Death or CV rehospitalization at day 182
  • Mean furosemide discharge dose (P=0.077):
  • Control: 164 mg
  • NT-proBNP-guided: 198 mg

Adapted from Castrini et al. J Cardiovasc Med. 2016;828-839.

slide-18
SLIDE 18

18

Outcomes (at 182 Days)

Adapted from Castrini et al. J Cardiovasc Med. 2016;828-839.

PRIMA II Trial

  • 400 patients, randomized 2011-2016 in 8 European

centers

  • Inclusion criteria:
  • ADHF admission
  • NT-proBNP ≥ 1700 ng/L
  • Patients first treated with usual care until clinical

stability, then randomized to:

  • Conventional treatment (blinded to NT-proBP

measurement), or

  • NT-proBNP-guided treatment (targeting >30% NT-

proBNP reduction from admission to discharge)

  • Followed treatment algorithm if NT-proBNP value <30%

reduction at randomization

  • Primary endpoint:
  • All-cause mortality and HF readmissions in 180 days after

randomization

Adapted from Steinen et al. J Card Fail. 2016;22:939-940.

Results: Still, Not Published, but...

Adapted from https://www.medpagetoday.com/meetingcoverage/hfsa/60345, accessed September 23, 2017

Results: Still, Not Published, but...

Adapted from https://www.medpagetoday.com/meetingcoverage/hfsa/60345, accessed September 23, 2017

slide-19
SLIDE 19

19

Outcomes (at 180 Days)

Adapted from https://www.medpagetoday.com/meetingcoverage/hfsa/60345, accessed September 23, 2017

How Should You Diurese Him?

1) IV loop diuretics in bid bolus doses 2) IV loop diuretics with continuous drip 3) Take your pick – it doesn’t matter.

How Should You Diurese Him?

1) IV loop diuretics in bid bolus doses 2) IV loop diuretics with continuous drip 3) Take your pick – it doesn’t matter.

Should We Give Bolus or Infusional IV Diuretics?

  • Multicenter, double-blind trial published in NEJM
  • ADHF patients, comparing:
  • Bolus dose every 12 hours vs. infusional
  • Low-dose vs. high-dose (no significant differences)
  • Primary endpoints:
  • Patients’ global assessment of symptoms
  • Change in serum Cr from baseline to 72 hours
slide-20
SLIDE 20

20 Global Assessment of Symptoms

Adapted from Felker et al. New Engl J Med. 2011;364:797-805.

Change in Creatinine

Adapted from Felker et al. New Engl J Med. 2011;364:797-805.

Death, Rehospitalization, or ED Visit

Adapted from Felker et al. New Engl J Med. 2011;364:797-805.

Patient #2

  • 76 y.o. woman with HTN is taken to the ER from

her 4th of July BBQ because of sudden SOB

  • PE: Wt 75 kg (baseline 74 kg) BP 185/110, HR

115, SaO2 85% RA, diffuse bibasilar rales.

  • Baseline meds: ASA 325 mg qd, HCTZ 25 mg qd,

amlodipine 10 mg qd, lisinopril 20 mg qd

  • CXR: Normal cardiac silhouette, diffuse

pulmonary edema

  • ECG: Sinus tachycardia at 115 bpm, LVH criteria

with repolarization abnormality

slide-21
SLIDE 21

21 Labs & Echo

  • Labs:
  • Na 137, K 4.1, Cr 1.6 (baseline 1.6)
  • NT-pro BNP 450, troponin I <0.1
  • ABG: 7.49/28/54 on RA
  • Baseline echo:
  • Normal LV size/function
  • Moderate LVH
  • 2+ MR

What Do You Do?

What should you do immediately?

1) Intubation, furosemide 2) BIPAP, sublingual nitroglycerin, furosemide 3) BIPAP, nitroglycerin drip, furosemide 4) BIPAP, dobutamine, furosemide

What Do You Do?

What should you do immediately?

1) Intubation, furosemide 2) BIPAP, sublingual nitroglycerin, furosemide 3) BIPAP, nitroglycerin drip, furosemide 4) BIPAP, dobutamine, furosemide

What is the Problem?

  • Characteristic findings in a patient who

develops “flash” pulmonary edema:

  • Poorly compliant ventricle (often with

LVH)

  • Can be worsened by ischemia
  • Small weight gain, relatively unimpressive

BNP

  • Often have significant mitral regurgitation
  • Almost always hypertensive at

presentation

slide-22
SLIDE 22

22 What is the Solution?

  • Patient is in a vicious cycle
  • Pulmonary edema/hypoxia à distress/raised

BP à worsened pulmonary edema/hypoxia

  • Pulmonary edema/hypoxia à ischemia à

worsened pulmonary edema/hypoxia

  • Time is of the essence – you are at a

crossroads

  • Quick, decisive action à rapid

improvement

  • Delayed (or unaggressive) action à

worsening of vicious cycle

How to Treat this Patient

  • Vasodilator at reasonable doses
  • Nitroglycerin (sublingual!)
  • Clevidipine/Nicardipine/Nitroprussid

e/Nesiritide

  • Diuresis
  • Important, but not as important
  • Respiratory support
  • Oxygen
  • BIPAP (also helps lower preload)
  • Intubation – beware sudden

hypotension!

What to Tell this Patient Long Term

  • This is the patient most sensitive to

sodium intake

  • Literally one indiscretion à flash

pulmonary edema

  • Focus on BP control
  • Role of ‘conventional’ heart failure

medications not clear

  • No indication for device therapy (e.g.

ICD, resynchronization)

  • Give this patient SL nitroglycerin tabs

at discharge!!!

Patient #3

  • 45 y.o. man with idiopathic dilated

cardiomyopathy à ER for nausea/vomiting, abdominal pain

  • Exam:
  • Vitals: AF BP 80/40 HR 120 RR 22 SaO2 95% RA
  • + scleral icterus/mild jaundice
  • JVP elevated to 20 cm H2O
  • Loud S3 gallop
  • Abd: Distended, diffusely tender but worst over RUQ,

equivocal Murphy’s sign

  • Ext: Clammy extremities, 2+ bilateral LE edema
slide-23
SLIDE 23

23 Meds/Labs

  • Outpatient meds:
  • Carvedilol 3.125 mg bid
  • Lisinopril 2.5 mg bid
  • Furosemide 80 mg bid
  • Digoxin 0.125 mg qd
  • Spironolactone 25 mg qd
  • Labs:
  • Na 128, K 5.6, Cr 2.0 (baseline 1.4)
  • Bilirubin 5.4 (baseline 1.0), Alk phos 180, INR 1.5,

AST 900, ALT 750

  • WBC 10k, NT-proBNP 3500, Lipase 60

Other Findings

  • CXR: Cardiomegaly, mild

interstitial thickening, no

  • bvious pulmonary edema
  • Baseline echo: Severe LV

dilatation, LVEF 20%, 3+ MR, 2-3+ TR, RVSP = 55 mmHg

ECG & Ultrasound

  • ECG: Sinus tach at 120,

nonspecific ST-T changes (unchanged from baseline except HR)

  • STAT RUQ U/S: +

gallbladder wall thickening possibly c/w cholecystitis, + ascites, normal CBD

What Do You Do?

1) Consult surgery for cholecystectomy 2) Start on Abx/fluids for cholecystitis 3) Diurese 4) Diurese/afterload reduce 5) Diurese/pressors 6) Diurese/inotropes

slide-24
SLIDE 24

24 What Do You Do?

1) Consult surgery for cholecystectomy 2) Start on Abx/fluids for cholecystitis 3) Diurese 4) Diurese/afterload reduce 5) Diurese/pressors 6) Diurese/inotropes

What is the Diagnosis?

  • Low output heart failure (e.g. cardiogenic shock)
  • Keys to the diagnosis: Low BP, elevated JVP, S3
  • Frequently present differently than you might think
  • GI complaints
  • Elevated LFTs (can be bili or transaminase pattern)
  • Worsened renal function
  • Much less common: Pulmonary edema/hypoxia

How to Functionally Manage This Patient

  • Augment forward flow
  • Afterload reduce if possible (cannot now due to

hypotension)

  • Inotrope (different from pressor!)
  • Diurese
  • Remember to look for an inciting cause!
  • Big-picture considerations
  • LVAD?
  • Transplant?
  • Hospice?

Inotropes vs. Pressors

  • These agents do three basic things:
  • Vasodilate
  • Vasoconstrict (“pressor”)
  • Inotropy
  • What agent to choose = what are you trying to

achieve?

  • Septic patient: Problem is inappropriate

vasodilatation à use vasoconstrictor

  • Hypertensive pulmonary edema (last patient):

Problem is inappropriate vasoconstriction à use vasodilator

  • Cardiogenic shock patient: Problem is weak

muscle/low cardiac output à use inotropic agent + vasodilator (as tolerated)

slide-25
SLIDE 25

25

IV Drips – From Vasodilators to Pressors

NTG/Nitroprusside/Nesiritide/ Nicardipine/Clevidipine Dobutamine/Milrinone Dopamine Epinephrine Norepinephrine Phenylephrine/Vasopressin

Vasodilatation Vasoconstriction Inotropy

Summary

  • Avoid term ‘heart failure exacerbation’
  • Multiple patients, multiple problems... multiple

treatments!

  • ‘Standard’ HF admission:
  • Remember: Digoxin, sacubitril-valsartan, salt

restriction, cardiac resynchronization

  • Generally avoid: Water restriction, loop

diuretic drips, targeting digoxin level

  • ‘Pressure overload’ admission: Vasodilate!
  • Sublingual NTG = most rapid/effective
  • ‘Low output’ admission:
  • Inotropic/mechanical support
  • Avoid ‘pressors’
  • Remember: Abdominal sx, tricky presentations

Final Thought: Question Dogma!

“Education consists mainly of what we have unlearned.”

  • Mark Twain

Thank you!

@Ron_Witteles